| Today's News and Trends | The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy. The single-dose gene therapy can help patients reduce their risk of bleeding events and discontinue factor IX prophylaxis therapy. | |
| A team of Mayo Clinic specialists led the analysis, sharing their findings in Nature Medicine. A team of Mayo Clinic specialists led the analysis, sharing their findings in Nature Medicine. | |
| The new study, published in JAMA Network Open, should help ease any concerns patients may have about regularly taking ADHD medications. The new study, published in JAMA Network Open, should help ease any concerns patients may have about regularly taking ADHD medications. | |
| | Two specialists with Hackensack University Medical Center in New Jersey performed the procedure. The patient, a 71-year-old woman, is doing well. Two specialists with Hackensack University Medical Center in New Jersey performed the procedure. The patient, a 71-year-old woman, is doing well. | |
| VT storm is associated with a heightened risk of death or significant complications. Early catheter ablation, it seems, is the most effective treatment option for this potentially fatal condition. VT storm is associated with a heightened risk of death or significant complications. Early catheter ablation, it seems, is the most effective treatment option for this potentially fatal condition. | |
| | Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022. Manesh R. Patel, MD, chair of AHA Scientific Sessions program, explains what he saw as the top takeaways from AHA 2022. | |
| The new study, published in Current Problems in Cardiology, included data from nearly 18,000 adult patients. The new study, published in Current Problems in Cardiology, included data from nearly 18,000 adult patients. | |
| | The use of NSAIDS such as ibuprofen and naproxen might not have the desired effect patients are seeking when it comes to joint pain, according to new findings to be presented at RSNA 2022. The use of NSAIDS such as ibuprofen and naproxen might not have the desired effect patients are seeking when it comes to joint pain, according to new findings to be presented at RSNA 2022. | |
| |
|
| | |
|